

CITATION REPORT

List of articles citing

Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study

DOI: 10.1038/sj.ki.5001542

Kidney International, 2006, 70, 351-7.

Source: <https://exaly.com/paper-pdf/40449636/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
272	Management of hyperphosphatemia. <i>Hemodialysis International</i> , 2006 , 10, 338-45	1.7	35
271	Mortality risk among hemodialysis patients receiving different vitamin D analogs. <i>Kidney International</i> , 2006 , 70, 1858-65	9.9	305
270	Emerging drugs for hyperphosphatemia. 2007 , 12, 355-65		23
269	Letter on the relation between serum Ca, PO ₄ , and PTH with mortality in dialysis patients. <i>Kidney International</i> , 2007 , 71, 178	9.9	1
268	Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients: the need for randomized trials. <i>Kidney International</i> , 2007 , 72, 909-11	9.9	17
267	Phosphorus balance and mineral metabolism with 3 h daily hemodialysis. <i>Kidney International</i> , 2007 , 71, 336-42	9.9	58
266	Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: results from the Third National Health and Nutrition Examination Survey (NHANES III). 2007 , 105, c178-84		43
265	Practical approaches to management of hyperphosphatemia: can we improve the current situation?. 2007 , 25, 120-4		21
264	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. 2007 , 2, 898-905		117
263	Bibliography. Current world literature. Parathyroids, bone and mineral metabolism. 2007 , 14, 494-501		
262	Bibliography. Current world literature. Mineral metabolism. 2007 , 16, 388-93		
261	Management of chronic kidney disease mineral-bone disorder. 2007 , 14, 44-53		12
260	Vitamin D levels and early mortality among incident hemodialysis patients. <i>Kidney International</i> , 2007 , 72, 1004-13	9.9	593
259	Mineral metabolism and mortality in patients with chronic kidney disease. 2007 , 14, 13-21		7
258	Vitamin D in patients with kidney disease: cautiously optimistic. 2007 , 14, 22-6		10
257	Vitamin D, cardiovascular disease, and survival in dialysis patients. <i>Journal of Bone and Mineral Research</i> , 2007 , 22 Suppl 2, V95-9	6.3	7
256	Patient empowerment in the management of hyperphosphatemia. <i>International Journal of Artificial Organs</i> , 2007 , 30, 1008-13	1.9	16

255	Il trattamento chirurgico dell'iperparatiroidismo nel paziente uremico: Ruolo attuale della paratiroidectomia: aspetti epidemiologici e nuove acquisizioni. 2007 , 19, 41-47	1
254	Mineral metabolism disturbances in patients with chronic kidney disease. 2007 , 37, 607-22	37
253	Vascular calcification--a new window on the cardiovascular system: role of agents used to manipulate skeletal integrity. 2007 , 20, 158-69	5
252	Evaluation and treatment of CKD patients before and at their first nephrologist encounter in Canada. 2007 , 50, 733-42	24
251	Clinical outcomes of elderly patients undergoing chronic peritoneal dialysis: experiences from one center and a review of the literature. 2007 , 39, 1295-302	33
250	CKD-MBD: impact on management of kidney disease. 2007 , 11, 261-268	13
249	Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients. 2008 , 12, 137-42	4
248	Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. 2008 , 51, S56-68	48
247	Racial differences in the competing risks of mortality and ESRD after acute myocardial infarction. 2008 , 52, 251-61	15
246	Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). 2008 , 52, 519-30	724
245	Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. 2008 , 52, 531-40	89
244	Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. 2008 , 359, 584-92	1320
243	Phosphate levels and blood pressure in incident hemodialysis patients: a longitudinal study. 2008 , 15, 321-31	4
242	Phosphate is a uremic toxin. 2008 , 18, 27-32	22
241	Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. 2008 , 88, 1511-8	248
240	25-hydroxyvitamin D levels and the risk of mortality in the general population. 2008 , 168, 1629-37	889
239	The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 963-72	4.3 117
238	Role of vitamin D receptor activators on cardiovascular risk. <i>Kidney International</i> , 2008 , S44-9	9.9 15

237	Serum phosphate levels and risk of infection in incident dialysis patients. 2008 , 3, 1398-406		19
236	Adynamic bone in patients with chronic kidney disease. <i>Kidney International</i> , 2008 , 73, 1345-54	9.9	80
235	Impact of activated vitamin D and race on survival among hemodialysis patients. 2008 , 19, 1379-88		145
234	Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. 2008 , 3, 1769-76		52
233	Vitamin D receptor activation and survival in chronic kidney disease. <i>Kidney International</i> , 2008 , 73, 1355-63	9.9	66
232	Vitamin D in chronic kidney disease: is the jury in?. <i>Kidney International</i> , 2008 , 74, 985-7	9.9	9
231	Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 703-6	4.3	11
230	The noncalcitropic actions of vitamin D: recent clinical developments. 2008 , 17, 408-15		44
229	Vitamin D and cardiovascular disease risk. 2008 , 11, 7-12		147
228	Vitamin D and glucose metabolism in chronic kidney disease. 2008 , 17, 566-72		39
227	The D-lemia for preventing secondary hyperparathyroidism in chronic kidney disease. 2008 , 14, 6-9		
226	Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. 2008 , 14, 18-27		30
225	Drugs Acting on the Calcium Receptor. 2008 , 1711-1735		1
224	Dialytic Phosphate Removal: A Modifiable Measure of Dialysis Efficacy in Automated Peritoneal Dialysis. 2009 , 29, 465-471		26
223	Lanthanum carbonate for hyperphosphatemia in patients with advanced CKD and patients receiving dialysis. 2009 , 4, 307-316		
222	The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism. <i>CKJ: Clinical Kidney Journal</i> , 2009 , 2, 205-12	4.5	5
221	Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. 2009 , 4, 1529-39		74
220	Phosphorus additives in food and their effect in dialysis patients. 2009 , 4, 1290-2		53

219	Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 2859-65	4.3	12
218	A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. <i>Kidney International</i> , 2009 , 76, 705-16	9.9	75
217	Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2009 , 2, 267-72	4.5	6
216	A new role for vitamin D receptor activation in chronic kidney disease. 2009 , 297, F1502-9		26
215	Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. 2009 , 48, 418-24		115
214	25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. 2009 , 20, 1805-12		212
213	Is calcitriol life-protective for patients with chronic kidney disease?. 2009 , 20, 2285-90		12
212	Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story. 2009 , 53, 183-8		12
211	Dietary phosphorus restriction in dialysis patients: potential impact of processed meat, poultry, and fish products as protein sources. 2009 , 54, 18-23		103
210	Association of reduction in bone mineral density with mortality in male hemodialysis patients. 2009 , 84, 180-5		18
209	Cardiovascular disease on hemodialysis: predictors of atherosclerosis and survival. <i>Hemodialysis International</i> , 2009 , 13, 278-85	1.7	17
208	Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. 2009 , 22, 357-62		15
207	Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. 2009 , 158, 395-412		46
206	Vitamin D levels and patient outcome in chronic kidney disease. <i>Kidney International</i> , 2009 , 75, 88-95	9.9	307
205	GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity. 2009 , 1792, 61-7		36
204	Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis. 2009 , 1792, 847-52		40
203	What can a keto acid/amino acid-supplemented protein-restricted diet do for the "butterfly effect" in chronic kidney disease patients?. 2009 , 19, S15-8		4
202	Vitamin D and the vasculature: can we teach an old drug new tricks?. 2009 , 13, 29-38		18

201	The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 3151-7	4.3	30
200	Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 1506-23	4.3	166
199	1,25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. 2009 , 204, 85-9		120
198	Clinical relevance of FGF-23 in chronic kidney disease. <i>Kidney International</i> , 2009 , S34-42	9.9	71
197	Trends and consequences of mineral bone disorder in haemodialysis patients: lessons from The Dialysis Outcomes and Practice Patterns Study (DOPPS). 2009 , 35 Suppl 1, 7-13		16
196	Chronic kidney disease-mineral and bone disorder (CKD-MBD): a new term for a complex approach. 2009 , 35 Suppl 1, 3-6		6
195	Vitamin D therapy for chronic kidney disease. 2009 , 29, 85-93		10
194	Role of vitamin D in chronic kidney disease. 2009 , 29, 113-21		24
193	Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. 2010 , 19, 335-42		25
192	Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications?. 2010 , 122, 194-7		
191	Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. 2010 , 42, 999-1006		17
190	Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). 2010 , 55, 77-87		91
189	Relation of serum phosphorus levels to carotid intima-media thickness in asymptomatic young adults (from the Bogalusa Heart Study). 2010 , 106, 793-7		30
188	Mineral and bone disorder and outcomes in hemodialysis patients: results from the DOPPS. 2010 , 23, 10-4		17
187	Intervista a Mario Cozzolino. 2010 , 22, 42-53		
186	Vitamin D Deficiency. 2010 , 115-127		3
185	Clinical measures identify vitamin D deficiency in dialysis. 2010 , 5, 460-7		63
184	Effects of an Innovative Educational Contest to Lower Serum Phosphorous Levels and Calcium-Phosphorous Products in Hemodialysis Patients. 2010 , 25, 345-350		1

183	Survival benefits with vitamin D receptor activation: new insights since 2003. 2010 , 5, 1704-9		13
182	Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis. 2010 , 5, 1710-6		110
181	Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. 2010 , 5, 582-9		39
180	Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. 2010 , 5, 1064-71		73
179	Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. <i>Kidney International</i> , 2010 , S10-21	9.9	97
178	Chronic Kidney Disease-Mineral Bone Disorder. 2010 , 98-114		
177	The effect of dialysis modality on phosphate control : haemodialysis compared to haemodiafiltration. The Pan Thames Renal Audit. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 897-901	4.3	49
176	Analysis of risk factors for mortality of incident patients commencing dialysis in East Yorkshire, UK. 2010 , 103, 41-8		7
175	Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. <i>American Journal of Nephrology</i> , 2010 , 32, 403-13	4.6	65
174	Vitamin D in kidney disease: pathophysiology and the utility of treatment. <i>Endocrinology and Metabolism Clinics of North America</i> , 2010 , 39, 355-63, table of contents	5.5	11
173	Dietary phosphate assessment in dialysis patients. 2010 , 20, 351-8		16
172	Oral phosphate binders in patients with kidney failure. 2010 , 362, 1312-24		252
171	Intravenous alfacalcidol once weekly pulse therapy for secondary hyperparathyroidism in hemodialysis patients. <i>Renal Failure</i> , 2011 , 33, 329-33	2.9	1
170	Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations. 2011 , 18, 120-31		25
169	Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes. 2011 , 5, 281-7		8
168	Dietary egg whites for phosphorus control in maintenance haemodialysis patients: a pilot study. 2011 , 37, 16-24		25
167	Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 1956-61	4.3	14
166	Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. 2011 , 223, 153-9		38

165	Shining D' light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. <i>Nephrology</i> , 2011 , 16, 351-67	2.2	16
164	Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?. 2011 , 24, 298-306		15
163	Elevated parathyroid hormone predicts mortality in dialysis patients undergoing valve surgery. 2011 , 150, 1095-101		10
162	Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. 2011 , 57, 415-21		39
161	Osteo-renal regulation of systemic phosphate metabolism. 2011 , 63, 240-7		35
160	Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 1938-47	4.3	108
159	Effect of post-dilutional on-line haemodiafiltration on serum calcium, phosphate and parathyroid hormone concentrations in uraemic patients. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 4032-7	4.3	24
158	Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 1340-6	4.3	20
157	Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients. 2011 , 6, 2650-6		22
156	Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis. <i>Indian Journal of Nephrology</i> , 2011 , 21, 245-9	0.8	16
155	UK Renal Registry 13th Annual Report (December 2010): Chapter 10: calcium, phosphate, parathyroid hormone, bicarbonate and total cholesterol concentrations amongst patients receiving haemodialysis or peritoneal dialysis in England, Wales and Northern Ireland in 2009: national and centre-specific analyses. 2011 , 119 Suppl 2, c179-214		1
154	Nutritional vitamin D in dialysis patients: what to D-iscern?. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 764-6	4.3	12
153	Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in peritoneal dialysis. 2011 , 6, 591-7		22
152	Clinical Significance of FGF-23 in Patients with CKD. <i>International Journal of Nephrology</i> , 2011 , 2011, 364890	4.7	30
151	Diagnostic Workup for Disorders of Bone and Mineral Metabolism in Patients with Chronic Kidney Disease in the Era of KDIGO Guidelines. <i>International Journal of Nephrology</i> , 2011 , 2011, 958798	1.7	3
150	Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. 2012 , 367, 2482-94		655
149	Chapter 9 Biochemical variables amongst UK adult dialysis patients in 2010: national and centre-specific analyses. 2012 , 120 Suppl 1, c175-210		3
148	Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. 2012 , 19, 11-8		64

147	The IMPACT (Incident Management of Patients, Actions Centered on Treatment) program: a quality improvement approach for caring for patients initiating long-term hemodialysis. 2012 , 60, 435-43		19
146	Vitamin D in kidney disease: pathophysiology and the utility of treatment. 2012 , 38, 115-23		3
145	Vitamin D therapy in chronic kidney disease and end stage renal disease. 2012 , 7, 358-65		76
144	Higher serum bone alkaline phosphatase as a predictor of mortality in male hemodialysis patients. 2012 , 90, 212-8		24
143	Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. 2012 , 21, 1232-9		22
142	Mineral and bone disorder in Chinese dialysis patients: a multicenter study. <i>BMC Nephrology</i> , 2012 , 13, 116	2.7	32
141	Practice pattern of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients in a tertiary care centre in India. 2012 , 33, 110-114		1
140	The immunoregulatory function of vitamin D: implications in chronic kidney disease. 2012 , 8, 403-12		46
139	A review of the reporting and handling of missing data in cohort studies with repeated assessment of exposure measures. 2012 , 12, 96		83
138	Vitamin d and stage 5 chronic kidney disease: a new paradigm?. 2012 , 25, 50-8		10
137	Improved long-term survival of dialysis patients after near-total parathyroidectomy. 2012 , 214, 400-7; discussion 407-8		71
136	Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. 2012 , 59, 58-66		58
135	Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis. <i>BMC Nephrology</i> , 2013 , 14, 88	2.7	38
134	Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China. <i>BMC Nephrology</i> , 2013 , 14, 29	2.7	17
133	Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. 2013 , 17, 247-88		220
132	Variations du calcium, du phosphore et de la parathormone au cours de l'insuffisance rénale chronique (IRC) en Côte d'Ivoire. 2013 , 37, 451-454		1
131	Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. <i>BMC Nephrology</i> , 2013 , 14, 199	2.7	64
130	Increased active PTH(1-84) fraction as a predictor of poor mortality in male hemodialysis patients. 2013 , 24, 2863-70		8

129	Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis. 2013 , 17, 72-7		8
128	Association of serum phosphorus concentration with mortality in elderly and nonelderly hemodialysis patients. 2013 , 23, 411-21		33
127	A pilot study of active vitamin D administration and insulin resistance in African American patients undergoing chronic hemodialysis. 2013 , 23, 185-93		6
126	Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. <i>American Journal of Nephrology</i> , 2013 , 37, 239-48	4.6	90
125	Cardiovascular Complications in Patients with Renal Disease. 2013 , 687-700		
124	Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients. 2013 , 17, 30-4		1
123	Impact of new vitamin D data on future studies and treatment. 2013 , 22, 377-82		5
122	Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 1241-54	4.3	34
121	Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. 2013 , 17, 221-8		101
120	Mineral metabolic abnormalities and mortality in dialysis patients. <i>Nutrients</i> , 2013 , 5, 1002-23	6.7	27
119	Calcium supplementation after parathyroidectomy in dialysis and renal transplant patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2014 , 7, 183-90	2.5	22
118	Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2014 , 7, 261-9	2.5	3
117	Calcium balance and negative impact of calcium load in peritoneal dialysis patients. 2014 , 34, 345-52		17
116	Bone-kidney axis in systemic phosphate turnover. 2014 , 561, 154-8		28
115	Oral active vitamin d treatment and mortality in maintenance hemodialysis patients. <i>CardioRenal Medicine</i> , 2014 , 4, 217-24	2.8	2
114	Bone mineral metabolism and subsequent hospitalization with poor quality of life in dialysis patients. <i>Nephro-Urology Monthly</i> , 2014 , 6, e14944	0.4	6
113	Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan. 2014 , 18 Suppl 1, 9-13		4
112	Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules. 2014 , 18 Suppl 1, 28-33		2

111	Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate. 2014 , 18 Suppl 1, 14-7		
110	Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients. 2014 , 18 Suppl 1, 2-8		
109	Is granular formulation of lanthanum carbonate more effective than chewable tablets?. 2014 , 18 Suppl 1, 23-7		
108	Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. 2014 , 21, 193-201		26
107	Vitamin D and the Immune System from the Nephrologist's Viewpoint. 2014 , 2014, 105456		15
106	Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up. <i>BMC Nephrology</i> , 2014 , 15, 20	2.7	16
105	Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review. 2014 , 27, 483-94		5
104	Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. 2014 , 13, 551-61		40
103	Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients. 2014 , 15, 1475-88		5
102	Aldosterone signaling and soluble adenylyl cyclase-a nexus for the kidney and vascular endothelium. 2014 , 1842, 2601-9		7
101	Stoornissen botmineraalhuishouding bij chronische nierschade. 2015 , 58, 630-633		
100	Vitamin D and Clinical Outcomes in Dialysis. 2015 , 28, 604-9		12
99	Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients. 2015 , 19, 235-44		10
98	Skin autofluorescence advanced glycosylation end products as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients. <i>Nephrology</i> , 2015 , 20, 862-7	2.2	15
97	Calcium and Sudden Cardiac Death in End-Stage Renal Disease. 2015 , 28, 624-35		10
96	An optical method for serum calcium and phosphorus level assessment during hemodialysis. <i>Toxins</i> , 2015 , 7, 719-27	4.9	7
95	Con: Phosphate binders in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 189-94	4.3	6
94	Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis. <i>American Journal of Nephrology</i> , 2015 , 42, 25-34	4.6	37

93	Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. 2015 , 10, 131-142		1
92	Uncorrected and Albumin-Corrected Calcium, Phosphorus, and Mortality in Patients Undergoing Maintenance Dialysis. 2015 , 26, 1671-81		54
91	Refining the definition of clinically important mineral and bone disorder in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 1336-44	4.3	14
90	La vitamine D et l'insuffisance rénale chronique : les douze points essentiels. 2015 , 39, 420-425		0
89	A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). 2015 , 10, 1031-40		60
88	Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 1542-51	4.3	98
87	Management of Mineral and Bone Disorders in Chronic Kidney Disease Patients. 2015 , 646-662		
86	The Value of the Model and Quantitative Parameters of Contrast-Enhanced Ultrasound in Judging the Severity of SHPT. <i>BioMed Research International</i> , 2016 , 2016, 6064526	3	3
85	Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients. 2016 , 101, 2440-9		19
84	Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L. 2016 , 20, 31-9		6
83	Lanthanum carbonate: safety data after 10 years. <i>Nephrology</i> , 2016 , 21, 987-994	2.2	41
82	Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease. 2016 , 12, 1206-1212		6
81	The association of mineral metabolism with vascular access patency. <i>Journal of Vascular Access</i> , 2016 , 17, 392-396	1.8	5
80	Phosphate equilibration rate and daily clearance in patients on CAPD, CCPD and APD. <i>International Journal of Artificial Organs</i> , 2017 , 39, 596-602	1.9	2
79	Lanthanum carbonate for dialysis patients with hyperphosphataemia resistant to sevelamer: A retrospective cohort study. 2016 , 3, 1262095		
78	Long-term observational study in Japanese hemodialysis patients who completed a 3-year clinical study of lanthanum carbonate. <i>Renal Replacement Therapy</i> , 2016 , 2,	2.3	1
77	Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2016 , 43, 85-96	4.6	23
76	Phosphate Removal by Peritoneal Dialysis: The Effect of Transporter Status and Peritoneal Dialysis Prescription. 2016 , 36, 85-93		14

75	Effects of vitamin D or its analogues on the mortality of patients with chronic kidney disease: an updated systematic review and meta-analysis. 2017 , 71, 683-693		24
74	Biomarkers associated with mortality in patients undergoing dialysis. 2017 , 43, 163-174		2
73	Roles of Serum Calcium, Phosphorus, PTH and ALP on Mortality in Peritoneal Dialysis Patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005-2012. <i>Scientific Reports</i> , 2017 , 7, 33	4.9	23
72	The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017 , 46, 983-1007	5.5	19
71	Worsening calcification propensity precedes all-cause and cardiovascular mortality in haemodialyzed patients. <i>Scientific Reports</i> , 2017 , 7, 13368	4.9	25
70	Phosphorus and mortality risk in end-stage renal disease: A meta-analysis. <i>Clinica Chimica Acta</i> , 2017 , 474, 108-113	6.2	24
69	Microwave ablation: an effective treatment for mild-to-moderate secondary hyperparathyroidism in patients undergoing haemodialysis. <i>International Journal of Hyperthermia</i> , 2017 , 33, 946-952	3.7	4
68	Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. <i>BMC Nephrology</i> , 2017 , 18, 206	2.7	32
67	Development and Validation of a Novel Laboratory-Specific Correction Equation for Total Serum Calcium and Its Association With Mortality Among Hemodialysis Patients. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 549-559	6.3	10
66	Vitamin D in Chronic Kidney Disease and Dialysis Patients. <i>Nutrients</i> , 2017 , 9,	6.7	119
65	Parathyroid Hormone Levels in the Prediction of Ischemic Stroke Risk. <i>Disease Markers</i> , 2017 , 2017, 43433171	3.7	7
64	Role of Vitamin D in Uremic Vascular Calcification. <i>BioMed Research International</i> , 2017 , 2017, 2803579	3	21
63	High Serum Alkaline Phosphatase, Hypercalcaemia, Race, and Mortality in South African Maintenance Haemodialysis Patients. <i>International Journal of Nephrology</i> , 2017 , 2017, 2795432	1.7	6
62	Low serum phosphate as an independent predictor of increased infection-related mortality in dialysis patients: A prospective multicenter cohort study. <i>PLoS ONE</i> , 2017 , 12, e0185853	3.7	7
61	Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials. <i>BMC Nephrology</i> , 2017 , 18, 272	2.7	6
60	Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017 , 10, 47-53	2.5	3
59	Dyslipidemia and risk of renal replacement therapy or death in incident pre-dialysis patients. <i>Scientific Reports</i> , 2018 , 8, 3130	4.9	5
58	Association of Pre-ESRD Serum Calcium With Post-ESRD Mortality Among Incident ESRD Patients: A Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1027-1036	6.3	10

57	Lanthanum-Induced Mucosal Alterations in the Stomach (Lanthanum Gastropathy): a Comparative Study Using an Animal Model. <i>Biological Trace Element Research</i> , 2018 , 185, 36-47	4.5	10
56	Hemodialysis versus peritoneal dialysis: an observational study in two international centers. <i>International Journal of Artificial Organs</i> , 2017 , 0	1.9	4
55	The Bone and Mineral Disorder in Patients Undergoing Chronic Peritoneal Dialysis. 2018 ,		
54	Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation. <i>Toxins</i> , 2018 , 10,	4.9	18
53	Calcitriol Accelerates Vascular Calcification Irrespective of Vitamin K Status in a Rat Model of Chronic Kidney Disease with Hyperphosphatemia and Secondary Hyperparathyroidism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018 , 366, 433-445	4.7	10
52	Rationale and study design of a randomized controlled trial for development of a treatment strategy for chronic kidney disease mineral and bone disorder by multilateral mechanism of etelcalcetide hydrochloride (the DUET study). <i>Renal Replacement Therapy</i> , 2019 , 5,	2.3	1
51	Active Vitamin D in Chronic Kidney Disease: Getting Right Back Where We Started from?. <i>Kidney Diseases (Basel, Switzerland)</i> , 2019 , 5, 59-68	3.3	11
50	Associations of serum and dialysate electrolytes with QT interval and prolongation in incident hemodialysis: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study. <i>BMC Nephrology</i> , 2019 , 20, 133	2.7	17
49	Outcomes of radiocephalic fistula created by nephrologists. <i>Journal of Vascular Access</i> , 2019 , 20, 615-620.	0.8	1
48	Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives. <i>International Journal of Nephrology and Renovascular Disease</i> , 2019 , 12, 263-276	2.5	25
47	Vitamin D Disorders in Chronic Kidney Disease. 2019 , 162-175.e7		
46	Management of Mineral and Bone Disorders in Chronic Kidney Disease. 2020 , 1013-1033		
45	Vitamin D receptor activation and prevention of arterial aging. 2020 , 409-425		
44	Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation. <i>Kidney Medicine</i> , 2020 , 2, 59-67	2.8	4
43	Markers of mineral metabolism and vascular access complications: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. <i>Hemodialysis International</i> , 2020 , 24, 43-51	1.7	1
42	Parathyroid Hormone Serum Levels and Mortality among Hemodialysis Patients in the Gulf Cooperation Council Countries: Results from the DOPPS (2012-2018).. <i>Kidney360</i> , 2020 , 1, 1083-1090	1.8	2
41	Glucagon-like peptide-1 receptor and sarcoglycan delta genetic variants can affect cardiovascular risk in chronic kidney disease patients under hemodialysis. <i>CKJ: Clinical Kidney Journal</i> , 2020 , 13, 666-673	4.5	1
40	Joint Longitudinal Low Calcium High Phosphorus Trajectory Associates with Accelerated Progression, Acute Coronary Syndrome and Mortality in Chronic Kidney Disease. <i>Scientific Reports</i> , 2020 , 10, 9682	4.9	7

39	Sevelamer Use, Vitamin K Levels, Vascular Calcifications, and Vertebral Fractures in Hemodialysis Patients: Results from the VIKI Study. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 500-509	6.3	6
38	The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 160-169	4.3	6
37	Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 2213-2220	4.5	8
36	Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance Hemodialysis. <i>American Journal of Nephrology</i> , 2021 , 52, 8-16	4.6	0
35	Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality. <i>CardioRenal Medicine</i> , 2021 , 11, 123-132	2.8	2
34	Serum phosphate and mortality in incident dialysis patients in Australia and New Zealand. <i>Nephrology</i> , 2021 , 26, 814-823	2.2	0
33	Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 , 12, 855-865	10.3	3
32	Effect of dialysis modality on the survival of end-stage renal disease patients starting dialysis in Sabah from 2007 to 2017: a retrospective cohort study.		
31	Treatment Of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD). 640-650		3
30	Vitamin D: Cardiovascular Function and Disease. 2011 , 115-142		2
29	Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: a retrospective study. <i>Singapore Medical Journal</i> , 2013 , 54, 263-6	1.9	3
28	Vitamin D and chronic kidney disease. <i>Korean Journal of Internal Medicine</i> , 2014 , 29, 416-27	2.5	30
27	Clinical Practice Guideline for CKD-MBD. <i>Nihon Toseki Igakkai Zasshi</i> , 2012 , 45, 301-356	0.3	14
26	Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease. <i>Indian Journal of Nephrology</i> , 2016 , 26, 239-43	0.8	4
25	Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?. <i>World Journal of Cardiology</i> , 2014 , 6, 216-26	2.1	15
24	Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia. <i>Drugs in Context</i> , 2017 , 6, 212302	5.2	2
23	Hemodialysis Patient with Diffuse Liver Calcification After Septic Shock. <i>American Journal of Case Reports</i> , 2021 , 22, e933386	1.3	
22	Role of Vitamin D and Vitamin D Analogs for Bone Health and Survival in Chronic Kidney Disease. 2010 , 955-965		

21	Role of Vitamin D for Cardiovascular Health. 2010 , 921-936		1
20	Dysphosphorfmes. 2011 , 79-103		
19	Variability of Serum Concentration of Calcium, Phosphate and Parathyroid Hormone Depending on Time of Blood Draw for Patients on Nocturnal Home Hemodialysis. <i>Open Journal of Nephrology</i> , 2012 , 02, 65-71	0	
18	Analysis of Adequacy of 25-Hydroxi vitamin D3 Supplementation in Patients on Hemodialysis and Parathormone, Calcium and Phosphorus Level in the Blood of These Patients. <i>Materia Socio-medica</i> , 2015 , 27, 83-6	0.9	
17	The association of abdominal obesity, obesity and parathyroid hormone in Korean adults (aged 80 years): The Korea National Health and Nutrition Survey, 2011. <i>Journal of the Korea Academia-Industrial Cooperation Society</i> , 2015 , 16, 3882-3888		2
16	Serum Levels of Intact Parathyroid Hormone, Calcium, and Phosphorus and Risk of Mortality in Hemodialysis Patients. <i>Nephro-Urology Monthly</i> , 2016 , 9,	0.4	3
15	Hypophosphatemic effect of niacin extended release in ischemic kidney disease. <i>EXCLI Journal</i> , 2015 , 14, 1095-103	2.4	
14	Association between Serum Inorganic Phosphorus Levels and Adverse Outcomes in Chronic Kidney Disease: The Fukushima CKD Cohort Study. <i>Internal Medicine</i> , 2021 ,	1.1	
13	Serum Phosphorus and Albumin in Patients Undergoing Peritoneal Dialysis: Interaction and Association With Mortality.. <i>Frontiers in Medicine</i> , 2021 , 8, 760394	4.9	1
12	Prevalence and risk factors for coronary artery disease in patients on chronic hemodialysis. <i>Medicinski Podmladak</i> , 2021 , 72, 34-39	0	
11	Dietary protein intake and the risk of all-cause and cardiovascular mortality in maintenance hemodialysis patients: A multicenter, prospective cohort study.. <i>Nutrition</i> , 2021 , 95, 111564	4.8	3
10	Protective Effects of Mitragyna inermis Roots Methanol Extract on Acetaminophen-Induced Hepatic Injuries in Wistar Rats. <i>Journal of Medical Sciences (Faisalabad, Pakistan)</i> , 2022 , 22, 13-21	0.5	
9	Ultrasound-guided thermal ablation for hyperparathyroidism: current status and prospects.. <i>International Journal of Hyperthermia</i> , 2022 , 39, 466-474	3.7	1
8	Optimal targets of chronic kidney disease-mineral and bone disorder markers for Chinese patients with maintenance peritoneal dialysis: a single-center retrospective cohort study.. <i>Renal Failure</i> , 2022 , 44, 336-345	2.9	2
7	Investigation on maintenance hemodialysis patients with mineral and bone disorder in Anhui province, China.		
6	Severe hyperparathyroidism is associated with nutritional impairment in maintenance hemodialysis patients. 9,		2
5	Evaluation of Laboratory Values Affecting Mortality of End-stage Renal Disease Patients: A Competing Risks Approach.		0
4	The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome. 13,		0

- 3 Chronic Kidney DiseaseMineral and Bone Disorder (CKD-MBD), from Bench to Bedside. **2023**, 3, 46-55 1
- 2 Anemia biomarkers and mortality in hemodialysis patients with or without diabetes: A 10-year follow-up study. **2023**, 18, e0280871 0
- 1 Mineral and Bone Disorder in CKD. **2023**, 131-145 0